4D Molecular Therapeutics (NASDAQ: FDMT) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $(0.53) by 181.13 percent. This is a 147.78 percent increase over losses of $(0.90) per share from the same period last year. The company reported quarterly sales of $85.090 million which beat the analyst consensus estimate of $32.245 million by 163.89 percent. This is a 8.51M percent increase over sales of $1.000 thousand the same period last year.